Custom Health Receives Buy Rating from Stifel and Announces Pharmacy Acquisition
Stifel has assigned a 'Buy' rating to Custom Health with a C$12 price target, citing the company's high medication adherence rates. The firm also highlighted potential upside as high as C$18 per share due to its innovative healthcare platform addressing non-adherence issues in the US market.
Tickers: $HUM
Topics: healthcare investment rating pharmacy deal